Subscribe Now Subscribe Today
Science Alert
Curve Top
American Journal of Drug Discovery and Development
  Year: 2014 | Volume: 4 | Issue: 1 | Page No.: 1-11
DOI: 10.3923/ajdd.2014.1.11
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Nanotechnologies for Boswellic Acids

Meenu Mehta, Saurabh Satija, Arun Nanda and Munish Garg

Boswellic Acids (BAs) are the main ingredients of Boswellia serrata (Family: Burseraceae) gum resin extract for the treatment of a variety of inflammatory diseases besides acting as both internal and external stimulant, expectorant, diuretic and stomachic. Despite its multipurpose benefits, BAs have low oral bioavailability especially 11-keto-β-boswellic acid (KBA) and 3-acetyl-11-keto-β-boswellic acid (AKBA), (the most therapeutically potential BAs) because these BAs are lipophilic in nature and not solubilises into the intestinal fluid thus limiting its systemic availability. For decades, many attempts have been made to compensate for these disadvantages, with the development of improved delivery platforms as the feasible approaches. The past ten years has witnessed the encouraging progress in the use of nano scale drug delivery systems on BAs such as loading BAs into liposomes, solid lipid nanoparticles as well as the latest reported technologies such as niosomes, phytosomes and nanomicelles etc. This review summarizes the recent works on the design and development of nanoscale delivery systems of BAs, with the goal of harnessing the true difficulties of this multifunctional agent in the clinical arena.
PDF Fulltext XML References Citation Report Citation
  •    Proniosomal Gel: A Promising Drug Carrier for Boswellic Acids
How to cite this article:

Meenu Mehta, Saurabh Satija, Arun Nanda and Munish Garg, 2014. Nanotechnologies for Boswellic Acids. American Journal of Drug Discovery and Development, 4: 1-11.

DOI: 10.3923/ajdd.2014.1.11






Curve Bottom